vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.7M, roughly 1.8× PureCycle Technologies, Inc.). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -697.1%, a 671.6% gap on every dollar of revenue. NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-42.0M).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.
NBY vs PCT — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $2.7M |
| Net Profit | $-1.2M | $-18.8M |
| Gross Margin | 65.2% | — |
| Operating Margin | -37.2% | -2196.1% |
| Net Margin | -25.5% | -697.1% |
| Revenue YoY | 126.1% | — |
| Net Profit YoY | 70.5% | 71.0% |
| EPS (diluted) | — | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.7M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | $4.8M | $0 | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $2.4M | $0 | ||
| Q1 24 | $2.6M | $0 |
| Q4 25 | — | $-18.8M | ||
| Q3 25 | — | $-28.4M | ||
| Q2 25 | — | $-144.2M | ||
| Q1 25 | — | $8.8M | ||
| Q4 24 | $-1.2M | $-64.7M | ||
| Q3 24 | $-1.2M | $-90.6M | ||
| Q2 24 | $-1.6M | $-48.2M | ||
| Q1 24 | $-3.2M | $-85.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — |
| Q4 25 | — | -2196.1% | ||
| Q3 25 | — | -1602.2% | ||
| Q2 25 | — | -2763.5% | ||
| Q1 25 | — | -2387.4% | ||
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | — | ||
| Q1 24 | -87.1% | — |
| Q4 25 | — | -697.1% | ||
| Q3 25 | — | -1167.5% | ||
| Q2 25 | — | -8741.8% | ||
| Q1 25 | — | 559.0% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | — | ||
| Q1 24 | -122.2% | — |
| Q4 25 | — | $-0.14 | ||
| Q3 25 | — | $-0.31 | ||
| Q2 25 | — | $-0.81 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | $-1.92 | $-0.54 | ||
| Q2 24 | $-1.37 | $-0.29 | ||
| Q1 24 | $-29.95 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $156.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $45.9M |
| Total Assets | $3.4M | $922.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $156.7M | ||
| Q3 25 | — | $234.4M | ||
| Q2 25 | — | $284.1M | ||
| Q1 25 | — | $22.5M | ||
| Q4 24 | $430.0K | $15.7M | ||
| Q3 24 | $776.0K | $83.7M | ||
| Q2 24 | $751.0K | $10.9M | ||
| Q1 24 | $1.8M | $25.0M |
| Q4 25 | — | $45.9M | ||
| Q3 25 | — | $68.2M | ||
| Q2 25 | — | $98.9M | ||
| Q1 25 | — | $238.2M | ||
| Q4 24 | $-129.0K | $180.4M | ||
| Q3 24 | $1.1M | $241.4M | ||
| Q2 24 | $-617.0K | $291.6M | ||
| Q1 24 | $160.0K | $336.8M |
| Q4 25 | — | $922.7M | ||
| Q3 25 | — | $989.1M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $787.3M | ||
| Q4 24 | $3.4M | $798.4M | ||
| Q3 24 | $3.9M | $788.8M | ||
| Q2 24 | $3.9M | $719.8M | ||
| Q1 24 | $5.4M | $734.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-28.7M |
| Free Cash FlowOCF − Capex | $-1.7M | $-42.0M |
| FCF MarginFCF / Revenue | -35.4% | -1559.6% |
| Capex IntensityCapex / Revenue | 0.1% | 495.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-183.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-28.7M | ||
| Q3 25 | — | $-38.5M | ||
| Q2 25 | — | $-36.7M | ||
| Q1 25 | — | $-38.9M | ||
| Q4 24 | $-1.7M | $-31.8M | ||
| Q3 24 | $-2.4M | $-33.4M | ||
| Q2 24 | $-1.4M | $-40.4M | ||
| Q1 24 | $-2.0M | $-39.2M |
| Q4 25 | — | $-42.0M | ||
| Q3 25 | — | $-42.4M | ||
| Q2 25 | — | $-45.3M | ||
| Q1 25 | — | $-53.9M | ||
| Q4 24 | $-1.7M | $-53.4M | ||
| Q3 24 | — | $-42.6M | ||
| Q2 24 | — | $-50.8M | ||
| Q1 24 | $-2.0M | $-53.5M |
| Q4 25 | — | -1559.6% | ||
| Q3 25 | — | -1743.1% | ||
| Q2 25 | — | -2747.1% | ||
| Q1 25 | — | -3409.6% | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | 495.1% | ||
| Q3 25 | — | 160.3% | ||
| Q2 25 | — | 521.5% | ||
| Q1 25 | — | 949.6% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
PCT
Segment breakdown not available.
